Exclusive Interviews

In this Exclusive Interview, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose in children with obesity.

In this Exclusive Interview transcript, Catherine L. Davis  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the surprising results of a study on exercise dose and obesity in children.

In this Exclusive Interview, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the Dexcom G6 CGM System and how the future of CGM will affect the way not only type 1, but also type 2 and prediabetes are treated.

In this Exclusive Interview transcript, Kevin Sayer  talks with Diabetes in Control Publisher Steve Freed  about the Dexcom G6 CGM System and the future of CGMs changing diabetes management for type 1, type 2, and even prediabetes. Click here to view the video interview. Steve Freed: This is Steve Freed …

In this Exclusive Interview, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about harnessing serotonin in the treatment of obesity and type 2 diabetes.

In this Exclusive Interview transcript, Lora K. Heisler talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about using serotonin in the treatment of obesity and type 2 diabetes.

In this Exclusive Interview, Mary de Groot talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about why people with diabetes have higher rates of depression, how depression differs from diabetes distress, and the effect of depression on diabetes management.

In this Exclusive Interview transcript, Mary de Groot talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about why people with diabetes have higher rates of depression, how depression differs from diabetes distress, and the effect of depression on diabetes management.

In this Exclusive Interview, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about diabetes drugs in the pipeline at Merck; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and the problem of "clinical inertia" in intensifying treatment.

In this Exclusive Interview transcript, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about how clinical inertia affects diabetes treatment; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and diabetes drugs in the Merck pipeline.